Evidence map›Paper›PMID 35245739›Full record

ArticleTuberculosis (Edinburgh, Scotland)2022

Enhanced immunogenicity of the tuberculosis subunit Rv0572c vaccine delivered in DMT liposome adjuvant as a BCG-booster.

Lirong Mao, Lifa Xu, Xiaochun Wang, Yingru Xing, Jian Wang, Yanpeng Zhang, Wei Yuan, Jianpeng Du, Zilun Shi, Jilei Ma and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tuberculosis (Edinburgh, Scotland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Lirong MaoDepartment of Immunology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, China.
Lifa XuDepartment of Immunology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, China. Electronic address: ahhnlfxu@126.com.
Xiaochun WangDepartment of Pathogen Biology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, China. Electronic address: wxcvieri@126.com.
Yingru XingDepartment of Immunology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, China; Department of Clinical Laboratory, Anhui Zhongke Gengjiu Hospital, Hefei, 230000, China.
Jian WangDepartment of Pathogen Biology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, China.
Yanpeng ZhangDepartment of Pathogen Biology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, China.
Wei YuanDepartment of Immunology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, China.
Jianpeng DuDepartment of Pathogen Biology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, China.
Zilun ShiDepartment of Clinical Laboratory, Affiliated Cancer Hospital, Anhui University of Science and Technology, Huainan, 232001, China.
Jilei MaDepartment of Clinical Laboratory, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, 450000, China.
Jingyan ZhangDepartment of Clinical Laboratory, Affiliated Heping Hospital, Changzhi Medical College, Changzhi, 046000, China.
Xiaohan ZhangDepartment of Pathogen Biology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, China.
Xinping WangDepartment of Immunology, School of Medicine, Anhui University of Science and Technology, Huainan, 232001, China.
Anhui University of Science and Technology · CNChangzhi Medical College · CNFirst Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 has affected the progress made in the prevention and treatment of tuberculosis (TB); hence, the mortality of tuberculosis has risen. Different strategies-based novel TB vaccine candidates have been developed. This study identifies strategies to overcome the limitations of Bacille Calmette-Guérin (BCG) in preventing latent infection and reactivation of TB. The latency antigen Rv0572c was selected based on the mechanism of interaction between Mycobacterium tuberculosis and its host. The rRv0572c protein was used to stimulate whole blood samples derived from patients with clinically diagnosed active TB (ATBs) or latent TB infections (LTBIs) and healthy control (HCs) donors, confirming that this protein can be recognized by T cells in patients with TB, especially LTBIs. C57BL/6 mice were used to investigate the immunogenicity of the rRv0572c protein emulsified in the liposome adjuvant dimethyldioctadecylammonium [DDA], monophosphoryl lipid A [MPLA], trehalose-6, 6'-dibehenate [TDB] (DMT). The results demonstrated that rRv0572c/DMT could boost BCG-primed mice to induce antigen-specific CD4

Indexed as

COVID-19Latent TuberculosisMycobacterium tuberculosisTuberculosisTuberculosis VaccinesAdjuvants, ImmunologicAnimalsAntigens, BacterialBCG VaccineCD8-Positive T-LymphocytesHumansLiposomesMiceMice, Inbred C57BLVaccines, SubunitAdjuvants, ImmunologicAntigens, BacterialBCG VaccineLiposomesTuberculosis VaccinesVaccines, SubunitAdjuvantDosR proteinLiposomeSubunit vaccineTuberculosis

Identifiers

PMID35245739
PMCPMC8881818
OpenAlexW4214520798

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.